Intellikine
Discovers and develops small molecule drugs that target signal transduction networks for the treatment of cancer, inflammation, and autoimmune disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
$310m (Public information from Dec 2011)
San Diego California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$12.5m | Seed | ||
$51.0m | Series B | ||
N/A | $4.0m | Early VC | |
N/A | $310m Valuation: $310m | Acquisition | |
Total Funding | $67.5m |